1.SpyGlass in Diagnosis of Hepatocellular Carcinoma with Right Hepatic Duct Tumor Thrombus Hemorrhage: A Case Report.
Li-Hua GUO ; Min MIAO ; Guo-Liang YE
Chinese Medical Sciences Journal 2023;38(4):309-314
Hepatocelluar carcinoma presenting as a biliary duct tumor thrombus is a relatively rare entity, with poor prognosis. The primary clinical manifestation of this disease is obstructive jaundice, which can often be misdiagnosed. A 59-year-old female patient was admitted with sudden onset of abdominal pain. Laboratory tests suggested obstructive jaundice, and enhanced magnetic resonance imaging of the upper abdomen did not show obvious biliary dilatation. Endoscopic ultrasound and endoscopic retrograde cholangiopancreatography suggested an occupying lesion in the upper bile duct. SpyGlass and biopsy finally confirmed hepatocellular carcinoma with right hepatic duct tumor thrombus hemorrhage. The SpyGlass Direct Visualization System, as an advanced biliary cholangioscopy device, showed the advantages of single-person operation as well as easy access to and visualization of the lesion.
Female
;
Humans
;
Middle Aged
;
Carcinoma, Hepatocellular/diagnostic imaging*
;
Jaundice, Obstructive/etiology*
;
Liver Neoplasms/diagnostic imaging*
;
Hepatic Duct, Common/pathology*
;
Thrombosis/complications*
;
Hemorrhage/complications*
2.Gadolinium Ethoxybenzyl Diethylene-triamine-pentaacetic-acid-enhanced Magnetic Resonance Imaging Perfusion and Multiple Hepatobiliary-phase Imaging for Quantitative Assessment of Liver Fibrosis in Rat Models.
Jia XU ; Xuan WANG ; Yan YOU ; Hua Dan XUE ; Qin WANG ; Shi Tian WANG ; Zheng Yu JIN
Acta Academiae Medicinae Sinicae 2018;40(6):809-816
Objective To investigate the value of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) in detecting different stages of liver fibrosis in rats.Methods Rat models of liver fibrosis were induced by carbon tetrachloride intraperitoneal injection for 4 - 12 weeks (n=45). The control group was applied with 0.9% saline (n=15). The MRI protocol contained both dynamic contrast-enhanced sequence (60 continuous scans within 3 minutes,including three pre-contrast measurements) and multiple hepatobiliary-phase acquisitions (every 5 minutes after contrast injection,60 minutes in total). METAVIR score was used to grade liver fibrosis:normal (F0),mild fibrosis (F1 - F2),and advanced fibrosis (F3 - F4). Liver perfusion parameters [transfer constant (K ),extravascular extracellular volume fraction (V),initial area under curve (iAUC),maximum relative enhancement (RE),and time of maximum RE (T)] as well as hepatobiliary-phase parameters [RE at different time point,the decrease of RE (RE=RE - RE),and elimination half-life of RE (T)] were measured and compared with ANOVA analysis and Spearman rank correlation.Results Thirty-one rats completed MRI exams and were then divided into normal (n=10),mild fibrosis (n=10),and advanced fibrosis (n=11) groups. K ,V and iAUC decreased as liver fibrosis progressed (r=-0.631,P=0.002;r=-0.503,P=0.017;r=-0.446,P=0.037). K and V showed significant differences among three groups(F=7.011,P=0.005;F=4.656,P=0.023). K and V were significantly lower in advanced fibrosis group than in normal group (P=0.001,P=0.009). There were statistical significant differences of T,T and RE among groups(F=6.633,P=0.005;F=5.493,P=0.010;F=5.343,P=0.014). Compared to normal and mild fibrosis groups,advanced fibrosis group had significantly longer T and T (P=0.005,P=0.004;P=0.008,P=0.008)and significantly lower RE(P=0.007,P=0.012).Conclusion Perfusion and multi-hepatobiliary-phase parameters such as K ,V,T, T and RE obtained from Gd-EOB-DTPA-enhanced MRI,may be valuable for detecting and staging liver fibrosis.
Animals
;
Contrast Media
;
chemistry
;
Gadolinium DTPA
;
chemistry
;
Liver
;
diagnostic imaging
;
pathology
;
Liver Cirrhosis
;
diagnostic imaging
;
Magnetic Resonance Imaging
;
Rats
3.Correlation Between Dual-energy and Perfusion CT in Patients with Focal Liver Lesions Using Third-generation Dual-source CT Scanner.
Jia XU ; Yongchang ZHENG ; Xuan WANG ; Huadan XUE ; Shitian WANG ; Jixiang LIANG ; Zhengyu JIN
Acta Academiae Medicinae Sinicae 2017;39(1):74-79
Objective To compare measurements of dual-energy CT iodine map parameters and liver perfusion CT parameters in patients with focal liver lesions using a third-generation dual-source CT scanner. Methods Between November 2015 and August 2016,33 patients with non-cystic focal lesions of liver were enrolled in this study. CT examinations were performed with a third-generation dual-source CT. The study CT protocol included a perfusion CT and dual-energy arterial and portal venous scans,with a time interval of 15 minutes. Iodine attenuation was measured at five region of interests including areas of high,medium,and low density within the lesion,as well as right and left liver parenchyma from the iodine map,while arterial liver perfusion (ALP),portal venous liver perfusion (PVP),and hepatic perfusion index (HPI) at the same location were measured from perfusion CT. The Pearson product-moment correlation coefficient was used to evaluate the relationship between iodine attenuation and perfusion parameters. Results The iodine attenuation at arterial phase showed significant intra-individual correlation with ALP (r=0.812,95% CI=0.728-0.885,P<0.001)and PVP (r=-0.209,95% CI=-0.323--0.073,P=0.007),but not significantly correlated with HPI (r=0.058,95% CI=0.046-0.498,P=0.461). The iodine attenuation at portal venous phase showed significant correlation with PVP (r=0.214,95% CI=0.072-0.361,P=0.005) but not with HPI(r=0.036,95% CI=-0.002-0.242,P=0.649). The mean effective dose of arterial phase and portal venous phase of dual-energy CT together [(3.53±1.17)mSv] was significantly lower than that of the perfusion CT [(14.53±0.45)mSv](t=25.212,P<0.001). Conclusion Iodine attenuation from arterial phase of dual energy CT demonstrates significant correlation with ALP and PVP,and iodine attenuation from portal venous phase demonstrates significant correlation with PVP.
Contrast Media
;
Humans
;
Iodine
;
Liver
;
diagnostic imaging
;
pathology
;
Perfusion
;
Portal Vein
;
Tomography, X-Ray Computed
;
methods
4.Primary adenosquamous carcinoma of the liver: a case report.
Clinical and Molecular Hepatology 2016;22(4):503-508
Adenosquamous carcinoma of the liver is a rare variant of cholangiocarcinoma. It is known to be a highly aggressive tumor with a poor prognosis, but its pathogenesis remains unclear owing to limited data in the literature. We report a case of 56-year-old woman who presented with a 1-week history of epigastric pain. Magnetic resonance imaging revealed a 6.5-cm ill-defined mass with low signal intensity in the left lobe of the liver, which was suspicious of cholangiocarcinoma. The patient underwent left hemihepatectomy. Microscopically, the tumor consisted of malignant glandular and squamous components and staged as pT2aN1. Despite postoperative chemoradiation, the patient had recurrence 8 months after surgery.
Abdomen/diagnostic imaging
;
Carcinoma, Adenosquamous/diagnostic imaging/*pathology
;
Cholangiopancreatography, Endoscopic Retrograde
;
Female
;
Gallstones/surgery
;
Humans
;
Liver Neoplasms/diagnostic imaging/*pathology
;
Middle Aged
;
Sphincterotomy, Endoscopic
;
Tomography, X-Ray Computed
5.Undifferentiated embryonal sarcoma of the liver in an adult patient.
Kyu Ho LEE ; Mussin Nadiar MARATOVICH ; Kyoung Bun LEE
Clinical and Molecular Hepatology 2016;22(2):292-295
Undifferentiated embryonal sarcoma of the liver (UESL) is rare primary hepatic sarcoma and is known to occur in pediatric patients. This case is the UESL occurred in a 51-year old male patient. Multilocular cystic lesion was composed of primitive spindle cells without specific differentiation. This rare case would help to review differential diagnosis of primary sarcoma in liver and cystic neoplasm of the liver.
Abdomen/diagnostic imaging
;
Biomarkers, Tumor/blood
;
Desmin/metabolism
;
Diagnosis, Differential
;
Humans
;
Immunohistochemistry
;
Liver Neoplasms/blood/*pathology/surgery
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Vimentin/metabolism
6.A case of portal hypertension by presumed as plexiform neurofibroma at the hepatic hilum.
Kyung Han LEE ; Sun Hong YOO ; Gi Tark NOH ; Won Suk HEO ; Byung Seong KO ; Jung Ah CHIO ; Hyo Jin CHO ; Jin Young CHOI ; Hee Jun KIM ; Won SOHN ; Sang Jong PARK ; Young Min PARK
Clinical and Molecular Hepatology 2016;22(2):276-280
Neurofibromas can occur anywhere in the body, but they usually involve the head, neck, pelvis, and extremities. Abdominal visceral involvement is rare, and intrahepatic involvement is even less common. We describe a patient who suffered from plexiform neurofibromatosis with liver involvement. A 49-year-old man, who had previously been diagnosed with neurofibromatosis, underwent esophagogastroduodenoscopy and abdominal ultrasonography for screening purposes. Esophagogastroduodenoscopy showed grade 2 esophageal varices and abdominal ultrasonography showed conglomerated nodules with echogenic appearances in the perihepatic space. Magnetic resonance imaging showed presumed plexiform neurofibroma involving the lesser sac and hepatic hilum and encasing the common hepatic artery celiac trunk and superior mesenteric artery left portal triad. We report an unusual case of portal hypertension attributed to the compressive narrowing of the portal vein by presumed as plexiform neurofibroma at the lesser sac and hepatic hilum.
Abdomen/diagnostic imaging
;
Endoscopy, Digestive System
;
Esophageal and Gastric Varices/pathology
;
Hepatic Artery/diagnostic imaging
;
Humans
;
Hypertension, Portal/*diagnosis
;
Liver/diagnostic imaging
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Neurofibroma, Plexiform/*diagnosis/diagnostic imaging
;
Tomography, X-Ray Computed
;
Ultrasonography
7.Drug-induced liver injury caused by iodine-131.
Chei Won KIM ; Ji Sun PARK ; Se Hwan OH ; Jae Hyung PARK ; Hyun Ik SHIM ; Jae Woong YOON ; Jin Seok PARK ; Seong Bin HONG ; Jun Mi KIM ; Trong Binh LE ; Jin Woo LEE
Clinical and Molecular Hepatology 2016;22(2):272-275
Iodine-131 is a radioisotope that is routinely used for the treatment of differentiated thyroid cancer after total or near-total thyroidectomy. However, there is some evidence that iodine-131 can induce liver injury . Here we report a rare case of drug-induced liver injury (DILI) caused by iodine-131 in a patient with regional lymph node metastasis after total thyroidectomy. A 47-year-old woman was admitted with elevated liver enzymes and symptoms of general weakness and nausea. Ten weeks earlier she had undergone a total thyroidectomy for papillary thyroid carcinoma and had subsequently been prescribed levothyroxine to reduce the level of thyroid-stimulating hormone. Eight weeks after surgery she underwent iodine-131 ablative therapy at a dose of 100 millicuries, and subsequently presented with acute hepatitis after 10 days. To rule out all possible causative factors, abdominal ultrasonography, endoscopic ultrasonography (on the biliary tree and gall bladder), and a liver biopsy were performed. DILI caused by iodine-131 was suspected. Oral prednisolone was started at 30 mg/day, to which the patient responded well.
Abdomen/diagnostic imaging
;
Chemical and Drug Induced Liver Injury/*diagnosis/drug therapy
;
Female
;
Humans
;
Iodine Radioisotopes/chemistry
;
Lymph Nodes/pathology
;
Lymphatic Metastasis
;
Middle Aged
;
Prednisolone/therapeutic use
;
Thyroid Neoplasms/drug therapy/surgery
;
Thyroidectomy
;
Thyroxine/therapeutic use
;
Ultrasonography
8.Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
Hyunwoo OH ; Dae Won JUN ; Waqar K SAEED ; Mindie H NGUYEN
Clinical and Molecular Hepatology 2016;22(3):327-335
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is a "hot potato" for pharmaceutical companies. Many clinical trials are underway to develop a first-in-class drug to treat NAFLD. However, there are several challenging issues regarding the diagnosis of NAFLD. Currently, liver biopsy is the gold standard method for the diagnosis of NAFLD and steatohepatitis. Ideally, globally recognized standards for histological diagnosis and methods to optimize observer agreement on biopsy interpretation should be developed. Liver biopsy is the best method rather than a perfect one. Recently, multi-parametric magnetic resonance imagery can estimate the amount of intrahepatic fat successfully and is widely used in clinical trials. But no diagnostic method can discriminate between steatohepatitis and simple steatosis. The other unresolved issue in regard to NAFLD is the absence of satisfactory treatment options. Vitamin E and obeticholic acid have shown protective effects in randomized controlled trials, but this drug has not been approved for use in Korea. This study will provide a description of diagnostic methods and treatments that are currently recommended for NAFLD.
Biomarkers/analysis
;
Chenodeoxycholic Acid/analogs & derivatives/therapeutic use
;
Clinical Trials as Topic
;
Fatty Liver/diagnosis
;
Fibrosis
;
Humans
;
Liver/diagnostic imaging/pathology
;
Magnetic Resonance Imaging
;
Non-alcoholic Fatty Liver Disease/*diagnosis/drug therapy
;
Tomography, X-Ray Computed
;
Ultrasonography
;
Vitamin E/therapeutic use
9.Liver transplantation for advanced hepatocellular carcinoma.
Clinical and Molecular Hepatology 2016;22(3):309-318
There has been ongoing debate that the Milan criteria may be too strict that a significant number of patients who could benefit from liver transplantation (LT) might have been excluded. Based on this idea, various studies have been conducted to further expand the Milan criteria and give more HCC patients a chance of cure. In deceased donor LT (DDLT) setting, expansion of the criteria is relatively tempered because the results of LT for HCC should be comparable to those of patients with non-malignant indications. On the other hand, in living donor LT (LDLT) situation, liver grafts are not public resources. The acceptable target outcomes for LDLT might be much lower than those for DDLT. Patients with biologically favorable tumors might have excellent survivals after LT despite morphological advanced HCCs. Therefore, the significance and utility of biological tumor parameters for selecting suitable LT candidates have been increased to predict HCC recurrence after LT. Although there is no consensus regarding the use of prognostic biomarkers in LT selection criteria for HCC, the combination of conventional morphological parameters and new promising biomarkers could help us refine and expand the LT criteria for HCC in the near future.
Biomarkers, Tumor/analysis
;
Carcinoma, Hepatocellular/diagnostic imaging/pathology/*therapy
;
Humans
;
Liver Neoplasms/diagnostic imaging/pathology/*therapy
;
Liver Transplantation
;
Neoplasm Recurrence, Local
;
Neoplasm Staging
;
Patient Selection
;
Positron-Emission Tomography
10.Evaluation of Liver Metastases Using Contrast-Enhanced Ultrasound: Enhancement Patterns and Influencing Factors.
Wen Tao KONG ; Zheng Biao JI ; Wen Ping WANG ; Hao CAI ; Bei Jian HUANG ; Hong DING
Gut and Liver 2016;10(2):283-287
BACKGROUND/AIMS: To evaluate the enhancement patterns of liver metastases and their influencing factors using dynamic contrast-enhanced ultrasound (CEUS). METHODS: A total of 240 patients (139 male and 101 female; 58.5±11.2 years of age) diagnosed with liver metastases in our hospital were enrolled in this study to evaluate tumor characteristics using CEUS. A comparison of enhancement patterns with tumor size and primary tumor type was performed using the chi-square test. The differences between quantitative variables were evaluated with the independent-sample t-test and one-way analysis of variance. RESULTS: The enhancement patterns of liver metastases on CEUS were categorized as diffuse homogeneous hyperenhancement (133/240, 55.4%), rim-like hyperenhancement (80/240, 33.3%), heterogeneous hyperenhancement (10/240, 4.2%), and isoenhancement (17/240, 7.1%). There were significant differences in the enhancement patterns during the arterial phase based on the nodule size (p=0.001). A total of 231 of the nodules showed complete washout during the portal phase, and 237 nodules were hypoenhanced during the delayed phase. The washout time was correlated with tumor vascularity, with a longer washout time observed in hypervascular metastases compared to hypovascular metastases (p=0.033). CONCLUSIONS: Diffuse homogeneous hyperenhancement followed by rapid washout was the most common enhancement pattern of liver metastases on CEUS and was affected by the nodule size and tumor vascularity. Small metastases were prone to show diffuse homogeneous hyperenhancement. Hyper-vascular metastases showed a significantly longer washout time compared to hypovascular metastases.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Contrast Media/*therapeutic use
;
Female
;
Humans
;
Liver/diagnostic imaging/pathology
;
Liver Neoplasms/blood supply/*diagnostic imaging/secondary
;
Male
;
Middle Aged
;
Neovascularization, Pathologic/diagnostic imaging
;
Ultrasonography/*methods
;
Young Adult

Result Analysis
Print
Save
E-mail